Shopping Cart
Remove All
Your shopping cart is currently empty
ACT-1004-1239
Copy Product Info
😃Good
Catalog No. T39665Cas No. 2178049-58-4
ACT-1004-1239 is an orally active, selective, and potent CXCR7 antagonist with immune-modulatory and myelin-promoting effects. It can be used to study inflammatory demyelinating diseases.
ACT-1004-1239
Copy Product Info😃Good
Purity: 98.31%
Catalog No. T39665Cas No. 2178049-58-4
ACT-1004-1239 is an orally active, selective, and potent CXCR7 antagonist with immune-modulatory and myelin-promoting effects. It can be used to study inflammatory demyelinating diseases.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $213 | In Stock | In Stock | |
| 5 mg | $538 | In Stock | In Stock | |
| 10 mg | $868 | - | In Stock | |
| 25 mg | $1,780 | - | In Stock | |
| 50 mg | $2,860 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $618 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:98.31%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | ACT-1004-1239 is an orally active, selective, and potent CXCR7 antagonist with immune-modulatory and myelin-promoting effects. It can be used to study inflammatory demyelinating diseases. |
| Targets&IC50 | CXCR7 (dog):2.3 nM, CXCR7 (human):3.2 nM |
| In vitro | ACT-1004-1239 inhibits CXCR7 in human, dog, rat, mouse, guinea pig and macaque with IC50s of 3.2, 2.3, 3.1, 2.3, 0.6 and 1.5 nM, respectively. [1] ACT-1004-1239 promotes the maturation of OPCs into myelin oligodendrocytes. [2] |
| In vivo | In a MOG-induced mouse model of EAE, ACT-1004-1239 treatment (10-100 mg/kg twice daily, orally) showed a significant dose-dependent reduction in the clinical score of the disease, leading to an increase in survival. At the highest dose tested (100 mg/kg twice daily), ACT-1004-1239 delayed disease onset and significantly reduced immune cell infiltration into the CNS and plasma filament light chain concentrations. [2] ACT-1004-1239 reduces pulmonary vascular permeability and reduces inflammatory cell infiltration. [3] |
| Molecular Weight | 522.55 |
| Formula | C27H28F2N6O3 |
| Cas No. | 2178049-58-4 |
| Smiles | N(C(=O)[C@@H]1[C@@H](NC(=O)C=2C=C(ON2)C3=C(F)C=C(F)C=C3)CCN(CC4CC4)C1)C5(CC5)C=6N=CC=CN6 |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 5.25 mg/mL (10.05 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy ACT-1004-1239 | purchase ACT-1004-1239 | ACT-1004-1239 cost | order ACT-1004-1239 | ACT-1004-1239 chemical structure | ACT-1004-1239 in vivo | ACT-1004-1239 in vitro | ACT-1004-1239 formula | ACT-1004-1239 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.